Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology TherapiesBusiness Wire • 06/16/22
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022Business Wire • 05/26/22
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022Business Wire • 05/26/22
Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 05/10/22
Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerBusiness Wire • 05/03/22
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022Business Wire • 04/26/22
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin's LymphomaBusiness Wire • 04/14/22